PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22927137-0	2012	Repeated dosing of piperine induced gene expression of P-glycoprotein via stimulated pregnane-X-receptor activity and altered pharmacokinetics of diltiazem in rats.	Diltiazem	146-155	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	55-69	
32078103-1	2020	BACKGROUND AND OBJECTIVES: P-glycoprotein (P-gp) has been shown previously to contribute to the intestinal absorption of verapamil, diltiazem, tacrolimus, colchicine and indinavir in situ; however, its contribution in vivo is unknown.	Diltiazem	132-141	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	27-41	
32078103-1	2020	BACKGROUND AND OBJECTIVES: P-glycoprotein (P-gp) has been shown previously to contribute to the intestinal absorption of verapamil, diltiazem, tacrolimus, colchicine and indinavir in situ; however, its contribution in vivo is unknown.	Diltiazem	132-141	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	43-47	
19069242-10	2008	The presence of EGCG significantly enhanced the oral bioavailability of diltiazem due to inhibiting cytochrome P450 (CYP) 3A4-mediated metabolism and P-glycoprotein (P-gp) mediated efflux of diltiazem in the intestine.	Diltiazem	72-81	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	150-164	
19069242-10	2008	The presence of EGCG significantly enhanced the oral bioavailability of diltiazem due to inhibiting cytochrome P450 (CYP) 3A4-mediated metabolism and P-glycoprotein (P-gp) mediated efflux of diltiazem in the intestine.	Diltiazem	72-81	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	166-170	
19069242-10	2008	The presence of EGCG significantly enhanced the oral bioavailability of diltiazem due to inhibiting cytochrome P450 (CYP) 3A4-mediated metabolism and P-glycoprotein (P-gp) mediated efflux of diltiazem in the intestine.	Diltiazem	191-200	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	150-164	
19069242-10	2008	The presence of EGCG significantly enhanced the oral bioavailability of diltiazem due to inhibiting cytochrome P450 (CYP) 3A4-mediated metabolism and P-glycoprotein (P-gp) mediated efflux of diltiazem in the intestine.	Diltiazem	191-200	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	166-170	
19035878-9	2008	In conclusion, resveratrol significantly increased the bioavailability of diltiazem due to the inhibition of both the cytochrome P450 (CYP) 3A4-mediated metabolism and the efflux pump P-glycoprotein (P-gp) in the intestine and/or liver.	Diltiazem	74-83	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	184-198	
19035878-9	2008	In conclusion, resveratrol significantly increased the bioavailability of diltiazem due to the inhibition of both the cytochrome P450 (CYP) 3A4-mediated metabolism and the efflux pump P-glycoprotein (P-gp) in the intestine and/or liver.	Diltiazem	74-83	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	200-204	
22358108-12	2011	The increase in diltiazem oral bioavailability might be attributable to enhanced absorption in the small intestine via the inhibition of P-gp and to reduced first-pass metabolism of diltiazem via the inhibition of the CYP3A subfamily in the small intestine and/or in the liver rather than renal elimination of diltiazem by simvastatin.	Diltiazem	16-25	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	137-141